{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T11:04:52Z","timestamp":1768215892182,"version":"3.49.0"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"1","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Summary:<\/jats:title>\n                  <jats:p>Resistance of chronic lymphocytic leukemia to BTK inhibitors poses a major clinical challenge; however, there is potential to overcome this obstacle by targeting the downstream protein kinase PKC\u03b2 using the novel inhibitor MS-553. By inhibiting PKC\u03b2, MS-553 blocks B-cell receptor signaling and WNT\/\u03b2-catenin and NF-\u03baB functions, thereby inducing apoptosis in BTK inhibitor\u2013resistant cells.<\/jats:p>\n                  <jats:p>See related article by Gordon et al., p. 85<\/jats:p>","DOI":"10.1158\/2643-3230.bcd-25-0390","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:02:03Z","timestamp":1765544523000},"page":"21-24","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overcoming BTK Inhibitor Resistance in Chronic Lymphocytic Leukemia by Targeting PKC\u03b2"],"prefix":"10.1158","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6188-1652","authenticated-orcid":false,"given":"Billy Michael Chelliah","family":"Jebaraj","sequence":"first","affiliation":[{"name":"Division of CLL, Department of Internal Medicine III, Ulm University, Ulm, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6830-9296","authenticated-orcid":false,"given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[{"name":"Division of CLL, Department of Internal Medicine III, Ulm University, Ulm, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"2026011203065951600_bib1","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41375-025-02662-y","article-title":"Resistance to targeted therapies in chronic lymphocytic leukemia: current status and perspectives for clinical and diagnostic practice","volume":"39","author":"Blombery","year":"2025","journal-title":"Leukemia"},{"key":"2026011203065951600_bib2","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"key":"2026011203065951600_bib3","article-title":"Genomic determinants of response and resistance to pirtobrutinib in relapsed\/refractory chronic lymphocytic leukemia","author":"Brown","year":"2025","journal-title":"Blood"},{"key":"2026011203065951600_bib4","doi-asserted-by":"crossref","first-page":"eadi5798","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"key":"2026011203065951600_bib5","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41375-024-02317-4","article-title":"Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance to BTK-degrader therapy in chronic lymphocytic leukemia","volume":"38","author":"Wong","year":"2024","journal-title":"Leukemia"},{"key":"2026011203065951600_bib6","first-page":"85","article-title":"The PKC\u03b2 inhibitor MS-553 displays preclinical efficacy including in BTK inhibitor resistant chronic lymphocytic leukemia","volume":"7","author":"Gordon","year":"2026","journal-title":"Blood Cancer Discov"},{"key":"2026011203065951600_bib7","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2008-06-160713","article-title":"PKC\u03b2 is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKC\u03b2 as a therapeutic target in chronic lymphocytic leukemia","volume":"113","author":"Holler","year":"2009","journal-title":"Blood"},{"key":"2026011203065951600_bib8","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/stem.3352","article-title":"Protein kinase C-\u03b2-dependent changes in the glucose metabolism of bone marrow stromal cells of chronic lymphocytic leukemia","volume":"39","author":"von Heydebrand","year":"2021","journal-title":"Stem Cells"},{"key":"2026011203065951600_bib9","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"F\u00fcrstenau","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026011203065951600_bib10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","article-title":"Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective","volume":"7","author":"Yang","year":"2022","journal-title":"Signal Transduct Target Ther"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-25-0390\/3714800\/bcd-25-0390.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/1\/21\/3723325\/bcd-25-0390.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/1\/21\/3723325\/bcd-25-0390.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:07:06Z","timestamp":1768205226000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/7\/1\/21\/771355\/Overcoming-BTK-Inhibitor-Resistance-in-Chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,12]]},"published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-25-0390","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]}}}